117 related articles for article (PubMed ID: 38823310)
21. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
22. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
[TBL] [Abstract][Full Text] [Related]
24. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors.
Liu L; Hussain M; Luo J; Duan A; Chen C; Tu Z; Zhang J
Chem Biol Drug Des; 2017 Mar; 89(3):420-427. PubMed ID: 27589335
[TBL] [Abstract][Full Text] [Related]
26. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
[TBL] [Abstract][Full Text] [Related]
27. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
[TBL] [Abstract][Full Text] [Related]
29. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
30. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W; Zhang K; Yao Y; Liu Y; Ni Y; Liao C; Tu Z; Qiu Y; Wang D; Chen D; Qiang L; Li Z; Jiang S
Eur J Med Chem; 2021 Feb; 211():113022. PubMed ID: 33239261
[TBL] [Abstract][Full Text] [Related]
31. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J
Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512
[TBL] [Abstract][Full Text] [Related]
32. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
[TBL] [Abstract][Full Text] [Related]
33. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor.
Li ZR; Suo FZ; Hu B; Guo YJ; Fu DJ; Yu B; Zheng YC; Liu HM
Bioorg Chem; 2019 Mar; 84():164-169. PubMed ID: 30502627
[TBL] [Abstract][Full Text] [Related]
34. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.
Li XY; Wang DP; Li S; Xue WH; Qian XH; Liu KL; Li YH; Lin QQ; Dong G; Meng FH; Jian LY
Bioorg Chem; 2022 Feb; 119():105469. PubMed ID: 34915285
[TBL] [Abstract][Full Text] [Related]
35. Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.
Thomson C; Barton P; Braybrooke E; Colclough N; Dong Z; Evans L; Floc'h N; Guérot C; Hargreaves D; Khurana P; Li S; Li X; Lister A; McCoull W; McWilliams L; Orme JP; Packer MJ; Swaih AM; Ward RA; Winlow P; Ye Y
J Med Chem; 2024 Jun; 67(11):8988-9027. PubMed ID: 38770784
[TBL] [Abstract][Full Text] [Related]
36. GRP78 blockade overcomes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer.
Park J; Purushothaman B; Hong S; Choi M; Jegal KH; Park M; Song JM; Kang KW
Life Sci; 2024 Jul; 348():122681. PubMed ID: 38697281
[TBL] [Abstract][Full Text] [Related]
37. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
38. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
39. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
40. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Wang X; Chen F; Gou S
Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
